)
Visual
test
Agenus
Agenus (AGEN) investor relations material
Agenus Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary16 Mar, 2026
Executive summary
BOT + BAL immunotherapy advanced to global Phase 3 trials for refractory MSS metastatic colorectal cancer, with early access programs expanding to over 30 countries and initial revenues recognized from these programs.
France expanded reimbursed access to include metastatic ovarian cancer and sarcoma, broadening patient reach and clinical experience.
Strategic collaboration with Zydus secured $91M upfront capital, dedicated U.S. biologics manufacturing, and a $20M contingent payment, strengthening the balance sheet and commercial readiness.
Financial highlights
Recognized $4.2M in net revenue from early access programs in 2025, with $3.2M in Q4 alone.
Other revenue, including non-cash royalty revenue, totaled $31.1M for Q4 and $14.4M for the full year.
Operating loss was $10.6M for Q4 and $110M for the full year; net loss was $20.2M for Q4 and $3.1M for the full year.
Outlook and guidance
Strategic priorities for 2026 include expanding patient access, advancing regulatory filings in the U.S. and EU, enrolling in the Phase 3 BATTMAN trial, and generating additional clinical data.
Revenue outlook for expanded French AAC access
Timeline for Zydus U.S. manufacturing transition
Biomarker impact on BATTMAN patient selection
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Agenus
- Zydus partnership secures manufacturing and capital, driving global access and pivotal trials for BOT/BAL.AGEN
Status update3 Feb 2026 - BOT/BAL data strong, cash up, but partnership losses and going concern risks persist.AGENQ2 20242 Feb 2026
- BOT/BAL shows robust efficacy in colorectal cancer, with pivotal trials and regulatory milestones ahead.AGENWells Fargo 2024 Healthcare Conference22 Jan 2026
- BOT/BAL shows strong efficacy in hard-to-treat cancers, with pivotal data and regulatory steps ahead.AGENH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
- Unprecedented clinical progress offsets losses, but urgent funding and asset sales are needed.AGENQ3 202415 Jan 2026
- BOT/BAL advances to Phase 3 with strong survival data and $91M Zydus funding secured.AGENQ2 20256 Jan 2026
- Reduced cash burn and BOT/BAL progress drive focus amid tight financials.AGENQ4 202426 Dec 2025
- Biotech registers 165,000 shares for warrant exercise, seeking capital amid ongoing financial risk.AGENRegistration Filing16 Dec 2025
- Shareholders will vote on director elections, equity plan amendments, and a one-time option exchange.AGENProxy Filing1 Dec 2025
Next Agenus earnings date
AGM 202631 Mar, 2026
Agenus
Next Agenus earnings date
AGM 202631 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage